Phase 3 Study of Recurrent Metastatic HNSCC with KEYTRUDA
As of June 11, 2019, Merck's KEYTRUDA is now FDA approved for first-line treatment of patients with metastatic or with unresectable, recurrent head and ...
5265 articles
As of June 11, 2019, Merck's KEYTRUDA is now FDA approved for first-line treatment of patients with metastatic or with unresectable, recurrent head and ...
Gerard Clum, D.C., Board Member of the Foundation for Chiropractic Progress, addresses the issues surrounding neck manipulation and strokes.
Paul MacKoul, one of the founders of The Center for Innovative GYN Care® (CIGC), discusses recent research that showed complex GYN issues are going und...
Doron Youngerwood, Director of Marketing at SysAid® Technologies, discusses their IT service management (ITSM) solution software that provides a suite ...
Mike Davis, Head of Neurology for UCB, a global biopharmaceutical company in the U.S., discusses the recent FDA approval of NAYZILAM® (midazolam) for t...
John Incledon, President of Hisamitsu America (the makers of Salonpas patches), discusses the Centers for Disease Control's recent recommendation for ph...
Ebele Mbanugo of Lagos, Nigeria, grand prize winner of the 2018 C3 (Changing Cancer Care) Prize, discusses her work, where she created a culturally-rele...
Susan Sheena, a mother of 4 boys, including a son diagnosed with schizophrenia at age 20, talks about her experience, what she wished she had known goin...
Alejandro Badia, founder of OrthoNOW® orthopedic urgent care centers, discusses innovations in treating tennis elbow and the newest treatment option fo...
Myopia, in simple terms is also called "nearsightedness." If you are myoptic, you see things more clearly when up close and see things blurred in the di...